drugset / Trial / NCT07811271
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Phase 3
Not yet recruiting
600 enrolled
BeOne Medicines
Asia-Pacific Gynecologic Oncology Trials Group · collabEuropean Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGOG Foundation · collabLatin American Cooperative Oncology Group (LACOG) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of BG-C9074 with bevacizumab (Arm A) versus bevacizumab monotherapy (Arm B) in adults with epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after firstline platinum-based chemotherapy plus bevacizumab.
Timeline
- Start
- 2026-10
- Primary completion
- 2029-11-30
- Completion
- 2033-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG-C9074 | Unknown | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |